BR112018012314A2 - método para síntese de ácido, e, métodos para preparar um quelato de dota metálico e gadoterato de meglumina. - Google Patents

método para síntese de ácido, e, métodos para preparar um quelato de dota metálico e gadoterato de meglumina.

Info

Publication number
BR112018012314A2
BR112018012314A2 BR112018012314A BR112018012314A BR112018012314A2 BR 112018012314 A2 BR112018012314 A2 BR 112018012314A2 BR 112018012314 A BR112018012314 A BR 112018012314A BR 112018012314 A BR112018012314 A BR 112018012314A BR 112018012314 A2 BR112018012314 A2 BR 112018012314A2
Authority
BR
Brazil
Prior art keywords
methods
preparing
metal
acid synthesis
dota
Prior art date
Application number
BR112018012314A
Other languages
English (en)
Other versions
BR112018012314B1 (pt
Inventor
Richard Meijer Andreas
Wang Aabye Arne
Gausemel Ingvil
Andre Haugan Jarle
Hussain Khalid
Jacob THANING Mikkel
Enes Nikolai
Sumihar Silalahi
Nilsen Sondre
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of BR112018012314A2 publication Critical patent/BR112018012314A2/pt
Publication of BR112018012314B1 publication Critical patent/BR112018012314B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B41/00—Formation or introduction of functional groups containing oxygen
    • C07B41/06—Formation or introduction of functional groups containing oxygen of carbonyl groups
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0063—Control or regulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente invenção provê métodos para a preparação de compostos úteis em aplicações terapêuticas e diagnósticas in vivo. em particular, a presente invenção provê um método para a síntese de ácido 1,4,7,10-tetra-azaciclododecano-1,4,7,10-tetra-acético (dota) e também métodos para a preparação de quelatos de metal de dota.
BR112018012314-5A 2015-12-18 2016-12-19 Método para síntese de ácido, e, métodos para preparar um quelato de dota metálico e gadoterato de meglumina BR112018012314B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1522412.4 2015-12-18
GBGB1522412.4A GB201522412D0 (en) 2015-12-18 2015-12-18 Dota synthesis
PCT/EP2016/081705 WO2017103258A1 (en) 2015-12-18 2016-12-19 Dota synthesis

Publications (2)

Publication Number Publication Date
BR112018012314A2 true BR112018012314A2 (pt) 2018-12-04
BR112018012314B1 BR112018012314B1 (pt) 2022-07-26

Family

ID=55311244

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018012314-5A BR112018012314B1 (pt) 2015-12-18 2016-12-19 Método para síntese de ácido, e, métodos para preparar um quelato de dota metálico e gadoterato de meglumina

Country Status (11)

Country Link
US (1) US10941124B2 (pt)
EP (1) EP3390373B1 (pt)
JP (3) JP2018537506A (pt)
KR (1) KR20180095001A (pt)
CN (1) CN108699012B (pt)
AU (1) AU2016369464B2 (pt)
BR (1) BR112018012314B1 (pt)
CA (1) CA3008703A1 (pt)
GB (1) GB201522412D0 (pt)
RU (1) RU2730519C2 (pt)
WO (1) WO2017103258A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522412D0 (en) 2015-12-18 2016-02-03 Ge Healthcare As Dota synthesis
KR20190088793A (ko) * 2018-01-19 2019-07-29 주식회사 엔지켐생명과학 칼코부트롤의 제조방법
CN113087680A (zh) * 2020-01-08 2021-07-09 威智医药有限公司 Dota晶型及其制备方法
KR20230022871A (ko) 2020-06-10 2023-02-16 후스테사 이마헨 에스.에이.유. 고순도 테트라크세탄(dota)으로부터 가도테레이트 메글루민을 수득하기 위한 절차 및 주사제 생약 제형의 제조에서의 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2596992B1 (fr) * 1986-04-11 1988-12-16 Guerbet Sa Sel de lysine du complexe gadolinium-dota et ses applications au diagnostic
NO20051911D0 (no) * 2005-04-19 2005-04-19 Amersham Health As Synthesis
AU2012342016C1 (en) * 2011-11-25 2016-09-01 Biophore India Pharmaceuticals Pvt. Ltd. Process for the purification of polyaminocarboxylates
CN102659702B (zh) * 2012-04-09 2014-12-03 武汉工程大学 一种1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸的纯化方法
EP2920156B9 (en) * 2012-10-02 2017-04-19 Guerbet Process for the preparation of macrocyclic polyazacarboxylate ligands and chelates
BR112015017675A2 (pt) * 2013-01-28 2017-07-11 Agfa Healthcare processo para a produção de 1, 4, 7, 10 – tetraazaciclododecano-1, 4, 7, 10-ácido tetra acético e complexos do mesmo
WO2015117911A1 (en) * 2014-02-06 2015-08-13 Agfa Healthcare Process for purifying 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
GB201522412D0 (en) 2015-12-18 2016-02-03 Ge Healthcare As Dota synthesis

Also Published As

Publication number Publication date
EP3390373A1 (en) 2018-10-24
US20180370925A1 (en) 2018-12-27
EP3390373C0 (en) 2023-12-13
GB201522412D0 (en) 2016-02-03
RU2730519C2 (ru) 2020-08-24
EP3390373B1 (en) 2023-12-13
CA3008703A1 (en) 2017-06-22
JP2023153826A (ja) 2023-10-18
AU2016369464B2 (en) 2020-12-03
RU2018122071A3 (pt) 2020-01-30
RU2018122071A (ru) 2020-01-20
US10941124B2 (en) 2021-03-09
JP2018537506A (ja) 2018-12-20
CN108699012A (zh) 2018-10-23
JP2021183615A (ja) 2021-12-02
CN108699012B (zh) 2022-08-02
AU2016369464A1 (en) 2018-07-05
KR20180095001A (ko) 2018-08-24
BR112018012314B1 (pt) 2022-07-26
WO2017103258A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
CY1124544T1 (el) Νεες χηλικες ενωσεις γαδολινιου για χρηση στη μαγνητικη τομογραφια
BR112018012314A2 (pt) método para síntese de ácido, e, métodos para preparar um quelato de dota metálico e gadoterato de meglumina.
PH12019500599A1 (en) Sweet flavor modifier
MX2022014611A (es) Compuestos para tomografia por emision de positrones.
MX2022002401A (es) Productos radiofarmaceuticos, agentes de radioimagenologia,y uso de los mismos.
MX2022014914A (es) Compuestos de interaccion con glicanos y metodos de uso.
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
JO3155B1 (ar) معدِّل نكهة حلوة
SA112330774B1 (ar) معدِّل نكهة حُلوة
MA34057B1 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
EA200701299A1 (ru) Производные стильбена и их применение для связывания и визуализации амилоидных бляшек
BR112014012822A8 (pt) Radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2
PH12020500164A1 (en) Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
MX2018000239A (es) Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.
EP3564218A4 (en) METHOD FOR PRODUCING 1,4,7,10-TETRAAZACYCLODODECAN-1,4,7,10-TETRAIC ACID
MX2016003725A (es) Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau.
MX2012012479A (es) Metodos, composiciones y accesorios para proporcionar un tratamiento terapeutico.
EP3045916A4 (en) Kit and method for diagnosis, prognosis or monitoring of liver disease through measurement of amount of ast
SG11201804307WA (en) Therapeutic agent for liver disease containing stromal cells derived from adipose tissue and method for producing the same
MX2013012795A (es) Procursores novedosos de derivados de glutamato.
EA201591449A1 (ru) Способы получения противораковых композиций
WO2013173746A3 (en) Fluorinated derivatives of 4-aminopyridine
EA202090569A1 (ru) Неинвазивная диагностика неалкогольных жировых дистрофий печени, неалкогольного стеатогепатита и/или фиброза печени
EA201891726A1 (ru) Лиганды для pet-визуализации тау-белков
NZ758917A (en) Compounds for positron emission tomography

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 257/02

Ipc: A61K 49/10 (2006.01), C07D 257/02 (2006.01)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/12/2016, OBSERVADAS AS CONDICOES LEGAIS